| URL | https://www.biopharmadive.com/news/moderna-coronav |
| Source | BIOPHARMADIVE |
| Date Published | 04/29/2021 |
| Author Name | Jonathan Gardner |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Moderna, Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Domestically, the work will be done: | Both |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Moderna Covid-19 vaccine |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Other, Covid-19, import replacement |